MedTrace Logo

Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

NCT04129736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-12-12

No results posted yet for this study

Summary

Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily

Conditions

  • Multiple Sclerosis, Pharmacokinetics

Interventions

DRUG

Teriflunomide 14 MG

Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis

Sponsors & Collaborators

  • Jan Lycke

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2021-03-31
Completion
2021-06-30
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129736 on ClinicalTrials.gov